Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity.

Pant V, Xiong S, Wasylishen AR, Larsson CA, Aryal NK, Chau G, Tailor RC, Lozano G.

Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17429-17437. doi: 10.1073/pnas.1909550116. Epub 2019 Aug 13.

PMID:
31409715
2.

Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.

Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM.

Eur Radiol. 2019 Aug 5. doi: 10.1007/s00330-019-06369-4. [Epub ahead of print] Review.

PMID:
31385048
3.

Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077.

Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, Magnus M, Liu AY, Panchia R, Hosseinipour MC, Kofron R, Margolis DA, Rinehart A, Adeyeye A, Burns D, McCauley M, Cohen MS, Currier JS.

Clin Infect Dis. 2019 May 24. pii: ciz439. doi: 10.1093/cid/ciz439. [Epub ahead of print]

PMID:
31125395
4.

Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection.

Young SH, Chau GY, Lee IC, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Lee MH, Huang YH.

J Formos Med Assoc. 2019 May 16. pii: S0929-6646(18)30891-X. doi: 10.1016/j.jfma.2019.04.018. [Epub ahead of print]

5.

Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.

Chi CT, Chau GY, Lee RC, Chen YY, Lei HJ, Hou MC, Chao Y, Huang YH.

J Formos Med Assoc. 2019 Mar 12. pii: S0929-6646(18)30861-1. doi: 10.1016/j.jfma.2019.02.012. [Epub ahead of print]

6.

The Longitudinal Effects of Non-injection Substance Use on Sustained HIV Viral Load Undetectability Among MSM and Heterosexual Men in Brazil and Thailand: The Role of ART Adherence and Depressive Symptoms (HPTN 063).

Tsuyuki K, Shoptaw SJ, Ransome Y, Chau G, Rodriguez-Diaz CE, Friedman RK, Srithanaviboonchai K, Li S, Mimiaga MJ, Mayer KH, Safren SA.

AIDS Behav. 2019 Mar;23(3):649-660. doi: 10.1007/s10461-019-02415-w.

PMID:
30725397
7.

A single extra copy of Down syndrome critical region 1-4 results in impaired hepatic glucose homeostasis.

Seo DS, Chau GC, Baek KH, Um SH.

Mol Metab. 2019 Mar;21:82-89. doi: 10.1016/j.molmet.2018.12.002. Epub 2018 Dec 5.

8.

Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelial-Mesenchymal Transition Regulators and Stemness Genes.

Chen CL, Tsai YS, Huang YH, Liang YJ, Sun YY, Su CW, Chau GY, Yeh YC, Chang YS, Hu JT, Wu JC.

Hepatol Commun. 2018 Sep 28;2(11):1392-1407. doi: 10.1002/hep4.1229. eCollection 2018 Nov.

9.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ.

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov.

10.

Synchronous hepatocellular carcinoma and lymphoepithelioma-like carcinoma arising from 2 different sites of the liver: A case report.

Shih EJ, Chau IY, Yeh YC, Chau GY.

Medicine (Baltimore). 2018 Oct;97(40):e12548. doi: 10.1097/MD.0000000000012548.

11.

Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases.

Zhang Y, Xiong S, Liu B, Pant V, Celii F, Chau G, Elizondo-Fraire AC, Yang P, You MJ, El-Naggar AK, Navin NE, Lozano G.

Nat Commun. 2018 Sep 27;9(1):3953. doi: 10.1038/s41467-018-06146-9.

12.

A Locally Adaptive Phase Aberration Correction (LAPAC) Method for Synthetic Aperture Sequences.

Chau G, Jakovljevic M, Lavarello R, Dahl J.

Ultrason Imaging. 2019 Jan;41(1):3-16. doi: 10.1177/0161734618796556. Epub 2018 Sep 15.

PMID:
30222052
13.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM.

Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14.

14.

Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma.

Chang CY, Hsieh WY, Chau GY, Chen PH, Su CW, Hou MC, Lei HJ, Huo TI, Huang YH, Lin HC, Wu JC.

Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1368-1377. doi: 10.1097/MEG.0000000000001193.

PMID:
29994873
15.

Daxx Functions Are p53-Independent In Vivo.

Wasylishen AR, Estrella JS, Pant V, Chau GP, Lozano G.

Mol Cancer Res. 2018 Oct;16(10):1523-1529. doi: 10.1158/1541-7786.MCR-18-0281. Epub 2018 Jun 14.

PMID:
29903771
16.

The fibronectin ED-A domain enhances recruitment of latent TGF-β-binding protein-1 to the fibroblast matrix.

Klingberg F, Chau G, Walraven M, Boo S, Koehler A, Chow ML, Olsen AL, Im M, Lodyga M, Wells RG, White ES, Hinz B.

J Cell Sci. 2018 Mar 1;131(5). pii: jcs201293. doi: 10.1242/jcs.201293.

17.

Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure.

Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH.

PLoS One. 2017 Nov 27;12(11):e0188552. doi: 10.1371/journal.pone.0188552. eCollection 2017.

18.

Small intestine follicular dendritic cell sarcoma with liver metastasis: A case report.

Chang YC, Chau IY, Yeh YC, Chau GY.

Medicine (Baltimore). 2017 Aug;96(31):e7261. doi: 10.1097/MD.0000000000007261.

19.

Effects of Phase Aberration and Phase Aberration Correction on the Minimum Variance Beamformer.

Chau G, Dahl J, Lavarello R.

Ultrason Imaging. 2018 Jan;40(1):15-34. doi: 10.1177/0161734617717768. Epub 2017 Jul 13.

PMID:
28703644
20.

mTOR controls ChREBP transcriptional activity and pancreatic β cell survival under diabetic stress.

Chau GC, Im DU, Kang TM, Bae JM, Kim W, Pyo S, Moon EY, Um SH.

J Cell Biol. 2017 Jul 3;216(7):2091-2105. doi: 10.1083/jcb.201701085. Epub 2017 Jun 12.

21.

Effects of phase aberration correction methods on the minimum variance beamformer.

Chau GR, Dahl JJ, Lavarello RJ.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:3231-3234. doi: 10.1109/EMBC.2016.7591417.

PMID:
28268996
22.

Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center.

Chang ME, Lei HJ, Chen MH, Yeh YC, Li CP, Hung YP, Hsia CY, Liu CA, Chau GY, Chao Y.

J Chin Med Assoc. 2017 Mar;80(3):140-146. doi: 10.1016/j.jcma.2016.09.010. Epub 2017 Feb 4.

23.

Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).

Chen I, Chau G, Wang J, Clarke W, Marzinke MA, Cummings V, Breaud A, Laeyendecker O, Fields SD, Griffith S, Scott HM, Shoptaw S, Del Rio C, Magnus M, Mannheimer S, Tieu HV, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH.

PLoS One. 2016 Dec 9;11(12):e0167629. doi: 10.1371/journal.pone.0167629. eCollection 2016.

24.

Distinct downstream targets manifest p53-dependent pathologies in mice.

Pant V, Xiong S, Chau G, Tsai K, Shetty G, Lozano G.

Oncogene. 2016 Nov 3;35(44):5713-5721. doi: 10.1038/onc.2016.111. Epub 2016 Apr 11.

25.

Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT, Kokudo N.

Liver Cancer. 2016 Oct;5(4):245-256. Epub 2016 Sep 14.

26.

The Formation of a Yin-Yang Gallbladder: A Case Report and Potential Clinical Implication.

Pan YA, Chau IY, Chau GY.

Gastroenterology. 2016 Nov;151(5):e1-e2. doi: 10.1053/j.gastro.2016.06.009. Epub 2016 Oct 3. No abstract available.

PMID:
27713046
27.

Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing.

Lin KT, Shann YJ, Chau GY, Hsu CN, Huang CY.

Oncogene. 2016 Sep 22;35(38):5078. doi: 10.1038/onc.2016.62. Epub 2016 Aug 1. No abstract available.

PMID:
27477694
28.

Temporal artifact minimization in sonoelastography through optimal selection of imaging parameters.

Torres G, Chau GR, Parker KJ, Castaneda B, Lavarello RJ.

J Acoust Soc Am. 2016 Jul;140(1):714. doi: 10.1121/1.4958997.

PMID:
27475192
29.

Ethanol-metabolizing activities and isozyme protein contents of alcohol and aldehyde dehydrogenases in human liver: phenotypic traits of the ADH1B*2 and ALDH2*2 variant gene alleles.

Chiang CP, Lai CL, Lee SP, Hsu WL, Chi YC, Gao HW, Yao CT, Chau GY, Yin SJ.

Pharmacogenet Genomics. 2016 Apr;26(4):184-195. doi: 10.1097/FPC.0000000000000205.

PMID:
26863581
30.

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J.

J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.

PMID:
26809111
31.

Hepatobiliary and Pancreatic: Focal peliosis hepatis mimicking hepatocellular carcinoma in a hepatitis B carrier.

Lai WJ, Chiu NC, Chau GY.

J Gastroenterol Hepatol. 2016 Jun;31(6):1073. doi: 10.1111/jgh.13237. No abstract available.

PMID:
26600454
32.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators.

Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.

PMID:
26361969
33.

S6K1 controls pancreatic β cell size independently of intrauterine growth restriction.

Um SH, Sticker-Jantscheff M, Chau GC, Vintersten K, Mueller M, Gangloff YG, Adams RH, Spetz JF, Elghazi L, Pfluger PT, Pende M, Bernal-Mizrachi E, Tauler A, Tschöp MH, Thomas G, Kozma SC.

J Clin Invest. 2015 Jul 1;125(7):2736-47. doi: 10.1172/JCI77030. Epub 2015 Jun 15.

34.

A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6.

Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC.

Medicine (Baltimore). 2014 Dec;93(29):e348. doi: 10.1097/MD.0000000000000348.

35.

Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection.

Su CW, Chau GY, Hung HH, Yeh YC, Lei HJ, Hsia CY, Lai CR, Lin HC, Wu JC.

Ann Surg Oncol. 2015 Jul;22(7):2253-61. doi: 10.1245/s10434-014-4221-5. Epub 2014 Dec 10.

PMID:
25490872
36.

Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

Chau GY.

World J Gastroenterol. 2014 Sep 21;20(35):12473-84. doi: 10.3748/wjg.v20.i35.12473. Review.

37.

Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11145-50. doi: 10.1073/pnas.1404139111. Epub 2014 Jul 14.

38.

Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.

Li Q, Zhang Y, El-Naggar AK, Xiong S, Yang P, Jackson JG, Chau G, Lozano G.

Mol Cancer Res. 2014 Jun;12(6):901-11. doi: 10.1158/1541-7786.MCR-14-0089. Epub 2014 Mar 5.

39.

Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC.

Wang HW, Hsieh TH, Huang SY, Chau GY, Tung CY, Su CW, Wu JC.

BMC Genomics. 2013 Oct 26;14:736. doi: 10.1186/1471-2164-14-736.

40.

Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing.

Lin KT, Shann YJ, Chau GY, Hsu CN, Huang CY.

Oncogene. 2014 Sep 25;33(39):4786-94. doi: 10.1038/onc.2013.424. Epub 2013 Oct 21. Erratum in: Oncogene. 2016 Sep 22;35(38):5078.

PMID:
24141781
41.

Dominance of the inactive Asian variant over activity and protein contents of mitochondrial aldehyde dehydrogenase 2 in human liver.

Lai CL, Yao CT, Chau GY, Yang LF, Kuo TY, Chiang CP, Yin SJ.

Alcohol Clin Exp Res. 2014 Jan;38(1):44-50. doi: 10.1111/acer.12215. Epub 2013 Aug 1.

PMID:
23909789
42.

Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma.

Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S616-24. doi: 10.1245/s10434-013-3101-8. Epub 2013 Jul 10.

PMID:
23838921
43.

Wandering abdominal pain due to a floating gallbladder.

Wu WC, Chau GY, Su CW, Wu JC.

Dig Liver Dis. 2013 Nov;45(11):e13. doi: 10.1016/j.dld.2013.05.003. Epub 2013 Jun 25. No abstract available.

PMID:
23806755
44.

The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy.

Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC.

PLoS One. 2013 Jun 21;8(6):e66457. doi: 10.1371/journal.pone.0066457. Print 2013.

45.

Significance of incorporation of model for end-stage liver disease score with TNM staging in patients with hepatocellular carcinoma undergoing hepatic resection.

Ling CH, Chau GY, Hsia CY, King KL.

Hepatogastroenterology. 2013 Jul-Aug;60(125):1142-7. doi: 10.5754/hge11939.

PMID:
23803377
46.

Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments.

Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC, Lin HC.

Int J Cancer. 2013 Dec 15;133(12):2895-902. doi: 10.1002/ijc.28311. Epub 2013 Jun 25.

47.

Baseline hypertension: new insight into the potential predictors of survival in patients with hepatocellular carcinoma.

Hu YF, Chen TC, Chau GY, Yang TL, Liu CJ, Chen MH, Chang PM, Chen TJ, Hsiao M, Huang CY, Chen SA.

Int J Cardiol. 2013 Oct 3;168(3):2979-81. doi: 10.1016/j.ijcard.2013.04.106. Epub 2013 May 7. No abstract available.

PMID:
23659881
48.

Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis.

Chen Z, Lai TC, Jan YH, Lin FM, Wang WC, Xiao H, Wang YT, Sun W, Cui X, Li YS, Fang T, Zhao H, Padmanabhan C, Sun R, Wang DL, Jin H, Chau GY, Huang HD, Hsiao M, Shyy JY.

J Clin Invest. 2013 Mar;123(3):1057-67. doi: 10.1172/JCI65344. Epub 2013 Feb 15.

49.

Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma.

Liu CH, Chen TC, Chau GY, Jan YH, Chen CH, Hsu CN, Lin KT, Juang YL, Lu PJ, Cheng HC, Chen MH, Chang CF, Ting YS, Kao CY, Hsiao M, Huang CY.

Mol Cell Proteomics. 2013 May;12(5):1335-49. doi: 10.1074/mcp.O112.020404. Epub 2013 Feb 8.

50.

Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection.

Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC.

J Gastrointest Surg. 2013 Apr;17(4):702-11. doi: 10.1007/s11605-012-2087-z. Epub 2012 Dec 6.

PMID:
23225107

Supplemental Content

Support Center